Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-24
2011-05-24
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S113000
Reexamination Certificate
active
07947706
ABSTRACT:
The invention relates to compounds of formula (I):wherein Ra, R1, Ar, L, A, W, Y, and Z are as defined in the disclosure; to compositions containing them; and to the preparation and use thereof, in particular as anticancer agents.
REFERENCES:
patent: 6897207 (2005-05-01), Cox et al.
patent: 7566736 (2009-07-01), Halley et al.
patent: 2005/0267304 (2005-12-01), Cox et al.
patent: WO 01/98299 (2001-12-01), None
patent: WO 03/000688 (2003-01-01), None
patent: WO 03/028724 (2003-04-01), None
patent: WO 03/082868 (2003-10-01), None
van Riggelen Jan et al., Nature cell biology, (Jan. 2010) vol. 12, No. 1, pp. 7-9.
Curtis et al., Bioorganic & Medicinal Chemistry Letters (1999), 9(4), 585-588.
Cammarei et al., Cancer Research, 70(11), 2010, pp. 4655-4665.
Oke et al., Cancer Research, vol. 69:(10), 2009, pp. 4150-4158.
Sood et al., The journal of clinical investigation, vol. 120(5), 2010, pp. 1515-1523.
Luo et al., Cancer Letters, vol. 289, 2010, pp. 127-139.
Lin et al., J. Clin. Invest., vol. 100(8), 1997, pp. 2072-2078.
Jean-Philippe Dales et al., International Journal of Oncology, vol. 22(2), 2003, pp. 391-397.
Severine Meunier-Carpentier et al., International of Oncology, vol. 26(4), 2005, pp. 977-984.
U.S. Appl. No. 11/832,206, filed Aug. 1, 2007, Ronan et al.
U.S. Appl. No. 11/832,208, filed Aug. 1, 2007, Ronan et al.
U.S. Appl. No. 11/757613, Office Action dated Jan. 16, 2009.
Asahara et al, Tie2 Receptor Ligands, Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-Induced Postnatal Neovascularization, Circ. Res., 1998 (83) pp. 233-240.
Bischoff et al, A homologue ofDrosophila aurorakinase is oncogenic and amplified in human colorectal cancers, EMBO; 1998 (17) 11 pp. 3052-3065.
Cary et al, Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn, Journal of Cell Science, 1996 (109), pp. 1787-1794.
Chen et al, Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase, Proc. Natl. Acad. Sci. USA, 1994 (91), pp. 10148-10152.
Davies et al, Inhibitor Binding to Active and Inactive CDK2: The Crystal Structure of CDK2-Cyclin A/Indirubin-5-Sulphonate, Structure, 2001 (9) pp. 389-397.
Davis et al, Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning, Cell, 1996 (87) pp. 1161-1169.
Dumont et al, Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo, Genes Dev., 1994 (8) pp. 1897-1909.
Kornberg et al, Cell Adhesion or Integrin Clustering Increases Phosphorylation of a Focal Adhesion-associated Tyrosine Kinase, J. Biol. Chem., 1992 (267) 33, pp. 23439-23442.
Lee et al, Anti-Vascular Endothelial Growth Factor Treatment Augments Tumor Radiation Response under Normoxic or Hypoxic Conditions 1, Cancer Research, 2000 (60) 19 pp. 5565-5570.
Lin et al, antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2, PNAS, 1998 (95) pp. 8829-8834.
Lin et al, Inhibition of Tumor Anglogenesis Using a soluble Receptor Establishes a Role for Tie2 in Pathologic Vascular Growth, J. Clin. Invest., 1997 (100) 8 pp. 2072-2078.
Ling et al, Malignant Astrocytoma Cell Attachment and Migration to Various Matrix Proteins Is Differentially Sensitive to Phosphoinositide 3-OH Kinase Inhibitors, J. Cell. Biochemistry, 1999 (73), pp. 533-544.
Maisonpierre et al, Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis, Science, 1997 (277) pp. 55-60.
Maung et al, requirement for focal adhesion kinase in tumor cell adhesion, Oncogene,1999 (18),pp. 6824-6828.
Millauer et al, Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo, Cancer Research, 1996 (56) pp. 1615-1620.
Oktay et al, Integrin-mediated Activation of Focal Adhesion Kinase Is Required for Signaling to Jun NH2-terminal Kinase and Progression through the G1 Phase of the Cell Cycle, J. Cell. Biol., 1999 (145) 7 pp. 1461-1469.
Owens et al, Overexpression of the Focal Adhesion Kinase (p125 FAK) in Invasive Human Tumors 1, Cancer Research, 1995 (55), pp. 2752-2755.
Richardson et al, A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125 FAK, Nature, 1996 (380), pp. 538-540.
Roy et al, Early Development of Cyclin Dependent Kinase Modulators, Current Pharmaceutical Design, 2001 (7) pp. 1669-1687.
Schaller et al, Autophosphorylation of the Focal Adhesion Kinase, pp125 FAK, Directs SH2-Dependent Binding of pp60src, Mol. Cell. Biol., 1994 (14), pp. 1680-1688.
Schlaepfer et al, Focal Adhesion Kinase Overexpression Enhances Ras-dependent Integrin Signaling to ERK2/Mitogen-activated Protein Kinase through Interactions with and Activation of c-Src, J. Biol. Chem., 1997 (272) 20, pp. 13189-13195.
Schlaepfer et al, Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase, Nature, 1994 (372) 22, pp. 786-791.
Schlaepfer et al, Signaling through focal adhesion kinase, Prog. Biophy. Mol. Biol., 1999 (71), pp. 435-478.
Sieg et al, Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration, J. Cell Science, 1999 (112), pp. 2677-2691.
Strawn et.al, Flk-1 as a Target for Tumor Growth Inhibition, Cancer Research, 1996 (56) pp. 3540-3545.
Suri et al, Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis, Cell, 1996 (87) pp. 1171-1180.
Toogood, Cyclin-Dependent Kinase Inhibitors for Treating Cancer, Med. Res. Rev., 2001 (21) 6 pp. 487-498.
Vuori et al, Induction of p130cas Signaling Complex Formation upon Integrin-Mediated Cell Adhesion: a Role for Src Family Kinases, Mol. Cell. Biol., 1996 (16) 6, pp. 2606-2613.
Wang et al, p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo, J. Cell Sci., 2000 (113), pp. 4221-4230.
Weiner et al, Expression of focal adhesion kinase gene and Invasive cancer, Lancet., 1993 (342), pp. 1024-1025.
Xing et al, Direct Interaction of v-Src with the Focal Adhesion Kinase Mediated by the Src SH2 Domain, Mol. Biol. of the Cell, 1994 (5), pp. 413-421.
Xu et al, Attenuation of the Expression of the Focal Adhesion Kinase Induces Apoptosis in Tumor Cells, Cell Growth Diff., 1996 (7), pp. 413-418.
Zhao et al, Regulation of the Cell Cycle by Focal Adhesion Kinase, J. Cell. Biol., 1998 (143) 7, pp. 1997-2008.
Bacque Eric
Desmazeau Pascal
Halley Frank
Ronan Baptiste
Souaille Catherine
Rahmani Niloofar
Sanofi-Aventis Deutschland GmbH
Scully , Scott, Murphy & Presser, P.C.
Seaman D. Margaret
LandOfFree
Substituted pyrrolopyridines, compositions containing them,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrrolopyridines, compositions containing them,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolopyridines, compositions containing them,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684041